Clinical Trial Update: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ocular toxicity risk and mitigation strategies for mirvetuximab soravtansine in patients with recurrent FR-α–positive ovarian cancer. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Elahere (mirvetuximab soravtansine)

Snippet

Sponsor: AbbVie | Conditions: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive | Phase 2 | Status: RECRUITING